Compare Illumina, Inc. (ILMN) vs NEOS S&P 500 High Income ETF (SPYI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs NEOS S&P 500 High Income ETF — how do they compare? Illumina, Inc. trades at $264.24 (market cap $40.43B), while NEOS S&P 500 High Income ETF trades at $54.02 (market cap $12.51B). The key difference: Illumina, Inc. is far larger — about 3.2× NEOS S&P 500 High Income ETF's market cap, and Illumina, Inc. is more actively traded (2,948,626 versus 2,751,602). Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and NEOS S&P 500 High Income ETF for 57 Days on average.
| ILMN | SPYI | |
|---|---|---|
Market Cap | $40.43B | $12.51B |
Volume | 2,948,626 | 2,751,602 |
Sector | Health | Income / Options Overlay |
52-Week High | $293.69 | $54.42 |
52-Week Low | $91.00 | $47.98 |
Typical Hold Time | 83 Days | 57 Days |
Enterprise Value | $41.79B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $264.40, down 3.34% on the day but up significantly year-to-date with strong technical momentum. The stock shows bullish moving average signals and trades near pivot point resistance at $268. Fundamentally, the company has delivered three consecutive quarterly earnings beats and returned to profitability in 2025 with $850 million net income after previous losses. Recent catalysts include S&P 500 inclusion effective September 21, 2026, and growing AI integration in genomics applications.
The outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI-driven biological data expansion, while risks involve China market headwinds and elevated valuation multiples. Earnings growth and S&P 500 inclusion provide near-term catalysts, but the stock trades at premium valuations with P/E of 49.96 requiring sustained execution.
SPYI trades at $54.01, down 0.13% with a bullish technical signal from moving averages. The ETF shows strong institutional interest as a covered-call income vehicle, though recent news highlights concerns about principal erosion from high-yield strategies. Technical indicators show RSI at overbought levels while support and resistance cluster around $54.
The outlook remains mixed with strong income generation potential offset by capital preservation risks. Recent coverage emphasizes the trade-off between high monthly distributions and potential long-term principal decline, requiring careful consideration for retirement income strategies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About NEOS S&P 500 High Income ETF
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →
